Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty

Journal of Invasive Cardiology

Volumn 12, Issue 10, 2000, Pages 497-501

  Fuchs, Shmuel ^b   Kornowski, Ran ^a   Mehran, Roxana ^b   Gruberg, Luis ^b   Satler, Lowell F ^b   Pichard, Augusto D ^b   Kent, Kenneth M ^b   Stone, Gregg W ^b   Leon, Martin B ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NONE

Author keywords

Abciximab; Angioplasty; Myocardial infarction; Stent

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; EMERGENCY TREATMENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COHORT STUDIES; EMERGENCY TREATMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034293157     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-1958.
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med 1997;336:1689-1696.
3. Topol EJ, Califf RM, Weisman HF, et al. on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC investigators. Lancet 1994;343:881-886.
4. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. The EPIC investigator group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997;278:479-484.
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
6. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. The c7E3 Fab antiplatelet therapy in unstable refractory angina (CAPTURE) study investigators. N Engl J Med 1999;340:1623-1629.
7. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30:1729-1734.
8. Haase KK, Mahrholdt H, Schroder S, et al. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1,332 patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J 1999;137:234-240.
9. Garbarz E, Farah B, Vuillemenot A, et al. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;82:800-803.
10. Piamsomboon C, Wong PM, Mathur A, et al. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions? Cathet Cardiovasc Interv 1999;46:415-420.
11. Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG trial investigators. Circulation 1998;97:857-864.
12. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391-395.
13. Aguirre FV, Topol EJ, Ferguson JJ, et al. for the EPIC investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC investigators. Circulation 1995;91:2882-2890.